Advancement in Therapeutic Intervention of Prebiotic-Based Nanoparticles for Colonic Diseases

Int J Nanomedicine. 2022 Dec 23:17:6639-6654. doi: 10.2147/IJN.S390102. eCollection 2022.

Abstract

Intestinal flora has become a therapeutic target for the intervention of colonic diseases (CDs) with better understanding of the interplay between microbiota and CDs. Depending on unique properties and prominent ability of regulating the intestinal flora, prebiotics can not only achieve a colon-specific drug delivery but also maintain the intestinal homeostasis, thus playing a positive role in the intervention of CDs. Currently, different studies on prebiotic-based nanoparticles have been contrived for colonic drug delivery and have shown great potential in curing various CDs, such as colitis and colorectal cancer. Nevertheless, there is a lack of systematic survey on the use of prebiotic nanoparticles for the treatment of CDs. This review aims to generalize the state-of-the-art of prebiotic nanomedicines specific for CDs. The species and function of intestinal flora and various kinds of prebiotics available as well as their regulating effects on intestinal flora were expounded. A variety of prebiotic nanoparticles pertinent to colon-targeted drug delivery systems were illustrated with particular emphasis on their curative activities on CDs. The efficacy and safety of prebiotic-based colonic drug delivery systems (p-CDDs) were also analyzed. In conclusion, the synergy between prebiotic nanoparticles and their cargos may hold promise for the treatment and intervention of CDs.

Keywords: colonic diseases; drug delivery; nanoparticles; prebiotics; therapeutic intervention.

Publication types

  • Review

MeSH terms

  • Colitis*
  • Humans
  • Nanoparticles*
  • Prebiotics

Substances

  • Prebiotics